OCTAGAM IMMUNE GLOBULIN (HUMAN): payments to doctors
Payments that named OCTAGAM IMMUNE GLOBULIN (HUMAN) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 8,528
- Transactions
- 27,779
- Average per transaction
- $45
The per-transaction average — $45 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,528 providers the average total is $145, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Octapharma USA, Inc. | $729,356 | 58.8% |
| Pfizer | $472,956 | 38.1% |
| Hospira, Inc. | $37,570 | 3.0% |
| PBG Puerto RICO LLC | $611 | 0.0% |